The Role of Cystatin C and Galectin-3 in Cardiorenal Syndrome
Article Sidebar
Main Article Content
Abstract
Acute heart disease patients often go on to develop worsening renal function, termed as cardiorenal syndrome. The growing breadth of studies has shown the implications of combining multiple biomarkers to better chart outcomes between heart and kidneys, and produce desirable results in such patients, as cystatin C and galectin-3
The aim: To estimate the levels of cystatin C and galectin-3, and their relationship with cardiorenal syndrome.
Methods: Cystatin C and galectin-3 were obtained from 144 samples: 50 sample with cardiorenal syndrome, 25 sample with heart disease, 25 sample with kidney disease and 44 normal healthy .
Results: A highly significant increase (p<0.0001) in the levels of cystatin C in serum of patients with cardirenal syndrome, heart disease and kidney disease compared with normal individuals. A highly significant (p<0.0001) increase in the serum levels of galectin-3 in patients with cardirenal syndrome and patients with heart disease, significant increase in the serum levels of galectin-3 and in patients with kidney disease when compared with control group
Conclusions: Cystatin C and galectin-3 have higher diagnostic validity values in the current study, which may be useful as a diagnostic tool to identify recurrence of the cardiorenal syndromes
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1. Wasiu A Olowu, Epidemiology, pathophysiology, clinical characteristics and management of childhood cardiorenal syndrome. World J Nephrol, 2012 :6; 1(1): 16-24.
2. Ronco C, McCullough P, Anker SD, et al., Cardio-renal syndromes: report from theconsensus conference of the acute dialysis quality initiative. Eur Heart J., 2010; 31: 703-711.
3. Bagshaw SM, Cruz DN, Aspromonte N, et al., Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus
Conference. Nephrol Dial Transplant, 2010; 25: 1406-1416.
4. Noora Ristiniemi, Quantification and clinical relevance of cystatin C,turun yliopisto. annals universitatis turkuensis, Turku, Finland., 2014.
5. Hanna Wallin, Cellular Uptake of Cystatin C, doctoral dissertation, Faculty of Medicine, defended at Segerfalksalen, BMC, Lund, 2013.
6. Song Li, Yangsheng Yu, Christopher D Koehn, et al., Galectins in the Pathogenesis of Rheumatoid Arthritis, Clin Cell Immunol., 2013,4:5.
7. Human cystatin C (Cys-C) ELISA Kit, Genasia biotech CO., LTD :Serial NO.:GA-E1121HM.
8. Galectin-3 Human ELISA Kit, CUSABIO BIOTECH CO., Ltd., Catalog No. CSB-EL012888HU
9. Kim EH, Yu JH, Lee SA, Kim, et al., Lack of association between serum cystatin c levels and coronary artery disease in diabetic patients. Korean Diabetes J, 2010 ; 34 : 95-100.
10. J.M. López Gómez , B. Sacristán Enciso , M. Micó , et al., Serum cystatin C and microalbuminuria in the detection of early-stage vascular and renal damage, in at-risk patients without chronic kidney disease. Official Publication of the Spanish Nephrology Society 2011;31(5):560-6.
11. Madhav Danthala , Lakshmaiah V., Correlative study of serum cystatin C levels with severity of acute ischemic stroke., Journal of Clinical and Biomedical Sciences J Clin Biomed Sci., 2013; 3(4):188-92.
12. Kshatriya S, Kozman H, Siddiqui D, et al., The cardiorenal syndrome in heart failure: An evolving paradigm. Am J Med Sci 2010;340:33-7.
13. Ahmed MS, Wong CF, Pai P., Cardiorenal syndrome — a new classification and current evidence on its management. Clin Nephrol., 2010;74:245-57.
14. Zhong-bao Ruan, Li Zhu, Yi-gang Yin, Ge-cai Chen, Cystatin C, N-terminal probrain natriuretic peptides and outcomes in acute heart failure with acute kidney injury in a 12-month follow-up: Insights into the cardiorenal syndrome. Journal of Research in Medical Sciences J Res Med Sci., 2014;19:404-9.
15. Sonia Triki ,Ons Fekih Ilhem Hellara , Fadoua Neffati , et al., Association between serum cystatin C levels andcardiovascular disease in type 2 diabetic patients. Ann Biol Clin., 2013; 71 (4): 438-42.
16. Ix JH, Shlipak MG, Chertow GM, Whooley MA., Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease. data from the Heart and Soul Study. Circulation, 2007 ; 115 : 173-9.
17. Carmen A. Peralta, Ronit Katz, Mark J. Sarnak, et al., Cystatin C Identifies Chronic Kidney Disease Patients at Higher Risk for Complications ,.J Am Soc Nephrol., 2011, 22: 147–155.
18. Tadashi Kaneko, Ryosuke Tsuruta, Shunji Kasaoka, et al., Increased serum cystatin C is a predictive factor for renal outcome in non-cardiac critically ill patients. Crit Care & Shock 2010. 13(1).
19. Vandana Menon, Michael G. Shlipak, Xuelei Wang, et al., Cystatin C as a Risk Factor for Outcomes in Chronic Kidney Disease. Ann Intern Med., 2007;147:19-27.
20. Shlipak MG, Katz R, Sarnak MJ, Fried LF, et al., Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med., 2006;145:237-46.
21. Christiane Drechsler, Graciela Delgado, Christoph Wanner, et al,. Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies. J AmSoc Nephrol., 2015, 26.
22. W. H. Wilson Tang, Kevin Shrestha, Zhili Shao, et al., Usefulness of Plasma Galectin-3 Levels in Systolic Heart Failure to Predict Renal Insufficiency and Survival, Am J Cardiol. 2011.
23. Jennifer E. Ho, Chunyu Liu, Asya Lyass, et al., Journal of the American College of Cardiology , Galectin-3, a Marker of Cardiac Fibrosis. Predicts Incident Heart Failure in the Community. 2012, 60(14).
24. Yu L, Ruifrok WP, Meissner M, et al., Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail., 2013;6(1):107-17.
25. Iacobini C,Menini S, Ricci C, et al., Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: Role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol., 2009, 29: 831–836.
26. Grandin EW, Jarolim P, Murphy SA, et al., Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI. Clin Chem., 2012 , 58:267- 273.
27. Pietro Ravani and Brendan J. Barrett, Galectin-3 and New-Onset CKD: Marker or Mediator?, J Am Soc Nephrol., 2013, 24: 1342–1344.
28. O’Seaghdha CM, Hwang SJ, Ho JE, et al., Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol 24: 1470–1477, 2013.
29. De Boer RA, van Veldhuisen DJ, Gansevoort RT, et al., The fibrosis marker galectin-3 and outcome in the general population. J Intern Med., 2012, 272: 55–64.
30. Gopal DM, Kommineni M, Ayalon N, et al., Relationship of plasma galectin-3 to renal function in patients with heart failure: Effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J AmHeart, 2012, Assoc 1: e000760.